The spinal serotoninergic projection from the raphe magnus has been shown to modulate nociceptive inputs, and activation of this projection mediates nicotine-elicited analgesia. Here, we investigate the interactions between cholinergic and serotoninergic systems in the spinal cord, by conducting serotonin [5-hydroxytryptamine (5-HT)] efflux experiments on mouse spinal slices. At least three spinal populations of nicotinic receptors are distinguished that affect 5-HT release. The first could be directly located on serotoninergic terminals, is insensitive to nanomolar concentrations of methyllicaconitine (MLA), and may be subjected to a basal (not maximal) cholinergic tone. The second is tonically and maximally activated by endogenous acetylcholine, insensitive to nanomolar concentrations of MLA, and present on inhibitory neurons. The last is also present on inhibitory neurons but is sensitive to nanomolar concentrations of MLA and not tonically activated by acetylcholine. Multiple nicotinic acetylcholine receptor populations thus differentially exert tonic or not tonic control on 5-HT transmission in the spinal cord. These receptors may be major targets for nicotine effects on antinociception. In addition, the presence of a tonic nicotinic modulation of 5-HT release indicates that endogenous acetylcholine plays a role in the physiological regulation of descending 5-HT pathways to the spinal cord. C holinomimetic drugs have long been shown to produce antinociception in animal models (1). Although early studies suggested an action via muscarinic receptors, it is now clear that nicotinic agonists exert strong antinociceptive actions. Epibatidine, a nicotinic agonist extracted from the skin of an Ecuadorian frog, has been shown to be 200 times more potent than morphine at blocking pain in animals (2), and some of its analogs are presently under clinical trial. Yet, the precise mechanism by which nicotinic agonists produce analgesia is far from completely understood.
The spinal serotoninergic projection from the raphe magnus has been shown to modulate nociceptive inputs, and activation of this projection mediates nicotine-elicited analgesia. Here, we investigate the interactions between cholinergic and serotoninergic systems in the spinal cord, by conducting serotonin [5-hydroxytryptamine (5-HT)] efflux experiments on mouse spinal slices. At least three spinal populations of nicotinic receptors are distinguished that affect 5-HT release. The first could be directly located on serotoninergic terminals, is insensitive to nanomolar concentrations of methyllicaconitine (MLA), and may be subjected to a basal (not maximal) cholinergic tone. The second is tonically and maximally activated by endogenous acetylcholine, insensitive to nanomolar concentrations of MLA, and present on inhibitory neurons. The last is also present on inhibitory neurons but is sensitive to nanomolar concentrations of MLA and not tonically activated by acetylcholine. Multiple nicotinic acetylcholine receptor populations thus differentially exert tonic or not tonic control on 5-HT transmission in the spinal cord. These receptors may be major targets for nicotine effects on antinociception. In addition, the presence of a tonic nicotinic modulation of 5-HT release indicates that endogenous acetylcholine plays a role in the physiological regulation of descending 5-HT pathways to the spinal cord. C holinomimetic drugs have long been shown to produce antinociception in animal models (1) . Although early studies suggested an action via muscarinic receptors, it is now clear that nicotinic agonists exert strong antinociceptive actions. Epibatidine, a nicotinic agonist extracted from the skin of an Ecuadorian frog, has been shown to be 200 times more potent than morphine at blocking pain in animals (2) , and some of its analogs are presently under clinical trial. Yet, the precise mechanism by which nicotinic agonists produce analgesia is far from completely understood.
Nicotine binds to nicotinic acetylcholine receptors (nAChRs), thus provoking the opening of their nonspecific cationic channel. nAChRs are transmembrane proteins formed of five subunits surrounding a central channel, with two (or five) ligand-binding sites (for hetero-or homopentamers, respectively) situated at the interface between subunits (3). Fifteen mammalian subunits (␣1-7, ␣9-10, ␤1-4, ␥, and ␦) have been cloned to date (4), and several combinations of these subunits may associate to produce functional receptors in vitro (5) .
In situ hybridization studies (6, 7) reveal that almost all nAChR subunits are expressed along the ascending nociceptive pathway (dorsal root ganglia, spinal cord, thalamus, and cortex), as well as in its descending modulatory correlates (rostro-ventral medulla). Moreover, binding experiments (8) clearly show a labeling of these regions by several nicotinic agonists and antagonists, suggesting that the expressed subunits indeed form receptors with intact binding sites in these regions. No preferential site for the analgesic effects of nicotine can therefore be deduced from such experiments.
In contrast, local injections of nicotinic drugs have shown that the serotoninergic descending control issuing from the raphe magnus may be of primary importance for nicotine-elicited analgesia (9, 10) . Among the seven strains of knockout (KO) mice constructed for one of the nAChR subunits (11) , only the ␣4-and the ␤2-KO mice have been analyzed to date in an analgesia paradigm (12) . In both strains not only were functional nAChRs eliminated from the raphe magnus, but the analgesic effect of nicotine in the ''hot plate'' test also was suppressed. However, in ␣4 (and to a lesser extent in ␤2) KO mice, nicotine still had antinociceptive effects in the ''tail flick'' test, although much reduced in comparison to wild-type mice (12) . These experiments suggest that there is a spinal (non-␣4␤2)-nAChR component of nicotinic analgesia. Indeed in the same study, electrophysiological experiments unraveled presynaptic (non-␣4␤2)-nAChRs in the dorsal horn of the spinal cord (12) .
In the present investigation, we continued the exploration of spinal presynaptic nAChRs by analyzing the effects of nicotinic agonists and antagonists on tritiated neurotransmitter efflux. As the descending serotoninergic projection from the raphe magnus appears relevant to the understanding of nicotine-induced analgesia, we examined interactions between cholinergic and serotoninergic systems in the spinal cord. In spinal slices, we show not only that nicotine elicits the release of 5-hydroxytryptamine (5-HT), but also that endogenous ACh modulates serotoninergic transmission in the spinal cord through nicotinic receptors.
Materials and Methods
Animals. C57 Black6 female mice (3 mo old) were purchased from Iffa Credo. Female ␣4 ϩ͞ϩ and ␣4Ϫ͞Ϫ mice, killed between 3 and 5 mo of age, were obtained from crossing of F 3 homozygotes (the KO and control animals were therefore cousins). Male ␤2 ϩ͞ϩ and ␤2Ϫ͞Ϫ mice, killed at 3 mo of age, were F 7 .
Drugs and Chemicals. [ 3 H]5-HT was purchased from Amersham Pharmacia (specific activity: 6.5-11.5 Ci͞mmol, depending on the batches). Agonists and antagonists were purchased from Sigma͞Research Biochemicals. The acetylcholine esterase (AChE) used was also purchased from Sigma and extracted from electric eel (activity: 1,070 units͞mg protein).
Preparation of Spinal Slices. Mice were decapitated and the spinal cords were rapidly dissected on ice. The thoracic spinal cords were then transversely cut (300 m) in a DSK-1000 slicer (Dosaka, Japan). The slices were collected and maintained for 30 min at room temperature in a Krebs buffer containing 120 mM NaCl, 2.5 mM KCl, 1.2 mM NaH 2 PO 4 , 2 mM CaCl 2 , 1.2 mM MgSO 4 , 25 mM NaHCO 3 , and 10 mM glucose, gassed with 95% to 5% O 2 ͞CO 2 mixture. This buffer is hereafter called superfusion buffer or SB. The slices were then incubated in the presence of 430 nM [ 3 H]5-HT and 10 mM pargyline in SB for 30
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Superfusion of Slices. Superfusion of slices was performed in home-made Plexiglas chambers (one spinal slice or two hemispinal slices per chamber) by using the SB at 37°C and at a rate of 0.5 ml͞min. The perfusate collected during the first 30 min was discarded, and subsequent superfusion fluid was collected in 1.25-ml (2.5 min) fractions. Drugs were added at the fourth collection period. When mentioned in the text, a preincubation of antagonist began 15 min before the collection period and continued until the end of the experiment. Fractions of perfusate were counted for radioactivity in a LKB Wallac (1209 RACK-BETA) counter after addition of 8 ml of biodegradable counting scintillant.
Superfusion Data Analysis. Drug-induced release was evaluated at the fifth and sixth collection period. The base line for the fifth and sixth collection periods was calculated from a linear extrapolation of the first four fractions of perfusate. The amplitude of the release is considered as the difference between the observed release and the base line calculated as described above and is expressed in percentage of the basal (mean of the first four fractions) release. Results are expressed as the mean Ϯ SEM of the values obtained in independent experiments, each experiment consisting of at least two replicate chambers for each condition. Fig. 1) , although the maximal effect was only 43% of the nicotine one.
Results

Effects of nAChR
Endogenously Activated nAChRs.
We then tested a number of nAChR antagonists on 5-HT release. Mecamylamine, dihydro-␤-erythroidine (Dh␤E), and hexamethonium, when applied alone, enhanced the release of [ 3 H]5-HT (n ϭ 2-60 depending on concentration) (Fig. 2) , whereas methyllicaconitine (MLA, 40 nM; Fig. 2 ) had no effect. The maximal response was observed after application of mecamylamine 30 M (30.8 Ϯ 2.2% increase, n ϭ 60). Because mecamylamine is known to also inhibit N-methyl-D-aspartate receptors, we tested whether another Nmethyl-D-aspartate receptor antagonist had a similar effect; 2-amino-5-phosphoentanoic acid (100 M) failed to modulate the basal release of [ 
Effects of nAChR Antagonists Preincubation on Nicotine-Elicited Ef-
fect. When nicotine was administered after preincubation with mecamylamine (30 M), Dh␤E (50 M), or hexamethonium (200 M), nicotine-elicited increase in 5-HT release was significantly antagonized (P ϭ 0.003, n ϭ 4; P ϭ 0.013, n ϭ 5; and P ϭ 0.0014, n ϭ 8, respectively) (Fig. 3) . In contrast, MLA, at a concentration (40 nM) considered to specifically block ␣7-subunit containing nAChRs (or ␣7*-nAChRs, following recommended nomenclature) (13) , potentiated the response to nicotine (n ϭ 6) (Fig. 3) .
Overall, these experiments suggest the existence of three main populations of nAChRs controlling, directly or indirectly, serotonine release in the spinal cord. The first, activated by agonists application, has an excitatory outcome; the second, tonically activated by endogenous ACh and inhibited by nicotinic antagonists application, has an inhibitory outcome. Finally, the data on MLA suggest that (i) the two receptor populations discussed above are composed of MLA-insensitive nAChRs, and (ii) there is a third nAChR population, possibly composed of ␣7*-nAChRs, which is not tonically activated and has an inhibitory effect on 5-HT release. Dose-response curve of the effects of nicotinic antagonists on [ 3 H]5-HT efflux from mouse spinal cord slices. MLA-(n ϭ 6), mecamylamine-(n ϭ 6 -60), hexamethonium-(n ϭ 3-6), and Dh␤E-(n ϭ 2-11) induced responses were compared to the control, SB, response. Statistical analysis according to one-way ANOVA followed by Dunnett's test for treatment vs.
control comparisons: ** , P Ͻ 0.01 and *** , P Ͻ 0.001. through nAChRs to modulate serotonin release, we modulated ACh levels by either inhibiting or increasing its breakdown. An AChE inhibitor, neostigmine (10 M), caused a 23% increase in [ 3 H]5-HT release (Ϯ1.4%, n ϭ 6) (Fig. 4) , suggesting that cholinergic activation of serotoninergic terminals is not maximal. The effects of neostigmine were insensitive to the muscarinic receptor inhibitor atropine (1 M, n ϭ 5) (Fig. 4) . These data provide further support to the notion that there exists a population of nAChRs whose activation leads to a potentiation of 5-HT transmission.
On the other hand, the application of AChE (from 10 ng to 30 g͞ml) enhanced the release of [ (Fig. 4) . This result confirms that a population of nAChRs, which inhibits 5-HT transmission, is tonically activated by endogenous ACh.
Block of the Inhibitory Transmission.
Given the excitatory nature of nicotinic transmission, the simplest explanation for the results obtained with nAChR agonists and antagonists as well as modulators of ACh metabolism is to assume (i) the existence of a population of nAChRs, which, directly or through an excitatory local circuit, activate 5-HT release, and (ii) a second nAChR population, which directly or through an excitatory local circuit, inhibits 5-HT transmission. To test this hypothesis, we decided to block the major inhibitory synaptic transmission in the spinal cord by incubating the slices with strychnine (1 M glycine receptor antagonist), saclofen [50 M ␥-aminobutyric acid type B (GABA B ) receptor antagonist], and bicuculline (40 M GABA A receptor antagonist).
This solution, that we refer to as I-mix, caused by its own a 59.3% (Ϯ 15%, n ϭ 6, result not shown) increase in the basal release of [ , n ϭ 29) (Fig. 5) , suggesting that the tonically activated nAChRs are mainly located on neurons which inhibit 5-HT transmission.
Effects of Nicotine on Serotonin Release in ␣4 and ␤2 KO Mice. Similar experiments were conducted in ␣4 and ␤2 KO mice to evaluate possible contributions of these two subunits to nicotine-elicited effects. In both strains, nicotine caused a dose-dependent increase that was not significantly different from that obtained in the corresponding control mice (n ϭ 3-7, depending on concentrations) (Fig. 6 ). These data support the notion that neither subunit is involved in the nicotinic control of 5-HT release in the spinal cord. (Fig. 1) . The simplest explanation for this result is that this population of nAChRs is directly expressed on serotoninergic terminals, although nAChRs on excitatory interneurons could have the same effect. These receptors are (i) insensitive to MLA (40 nM), (ii) are not maximally activated by endogenous ACh as they can still respond to nicotine, and (iii) may be subjected to a basal cholinergic tone, because neostigmine treatment enhances 5-HT release.
Second, mecamylamine (10-30 M), Dh␤E (50-200 M), and hexamethonium (200-500 M) but not MLA (40 nM) enhanced [ 3 H]5-HT release (Fig. 3) . This result implies the presence of a population of tonically activated nAChR, which are present on inhibitory neurons (or excitatory neurons impinging on inhibitory neurons) (Fig. 7) . In the spinal cord, the main inhibitory transmitters are GABA and glycine. It has even been demonstrated that 64% of GABAergic interneurons also express glycine (14) , and there is evidence that both transmitters are liberated at some synapses (15) . We therefore decided to inhibit these transmissions to evaluate the contribution of nAChRs present on other neurons. In these conditions, the effect of mecamylamine was markedly reduced (Fig. 6) , suggesting that the majority of endogenously activated nAChRs are present on GABAergic and͞or glycinergic neurons (or excitatory neurons affecting the inhibitory neurons). These receptors are (i) insensitive to MLA, (ii) tonically (because both nicotinic antagonists and AChE cause an increase in 5-HT release), and (iii) maximally activated by endogenous ACh. This last deduction derives from the finding that the effect of nicotine was not significantly different in the presence or in the absence of I-mix, a mixture of glycine and GABA receptor antagonists (Fig. 6) . Therefore, nicotine has no effect on the tonically activated nAChRs affecting inhibitory interneurons, which suggests that these receptors are already maximally activated.
Lastly, MLA (40 nM) alone had no effect on 5-HT release but could potentiate nicotine excitatory action (Fig. 2) . This indicates the existence of a third population of nAChRs, which is expressed by inhibitory neurons (or excitatory neurons impinging on them). These receptors are (i) MLA sensitive (which suggests an ␣7* composition) and (ii) not tonically activated by endogenous ACh.
Subunit Composition of nAChRs Modulating 5-HT Release in the Spinal
Cord. Previous evidence for the expression of nAChR subunit mRNA or protein as well as binding for nicotinic ligands in the spinal cord (6, 7, (16) (17) (18) The present data suggest that the nAChRs, which increase 5-HT release, do not contain either ␣4 or ␤2 (see data on KO mice) or ␣7 subunits (see lack of antagonism by MLA). Therefore, they do not correspond to the two major nAChR isoforms present in the rodent brain (19) (20) (21) , but to minor populations of (non-␣4␤2*)-nAChRs (12) . This result is consistent with the electrophysiological data obtained in ␣4 and ␤2 KO mice (12) , which revealed the presence of presynaptic (non-␣4␤2*) nAChRs in the dorsal horn of the spinal cord. Overall, it seems likely that nAChRs involved in the positive control of 5-HT release in the spinal cord have a unique composition and may even contain not yet cloned subunits. These data agree with a previous study on nicotinic binding in membranes from spinal cord, which led Khan and coworkers (22) to consider spinal nAChRs as forming a class of nAChRs different from those expressed in the brain and ganglia.
At least two nAChR populations are expressed on GABA͞ glycine neurons; one is sensitive to MLA (40 nM), whereas the other is insensitive to MLA but antagonized by mecamylamine, Dh␤E, and hexamethonium. According to current knowledge, the former population may be composed of ␣7*-nAChRs, although recent data show that other subunit combinations (without ␣7) may be sensitive to nM concentrations of MLA (23) . The presence of ␣7*-nAChR in the spinal cord is in agreement with previous reports of ␣-bungarotoxin binding in this region (6, 7, (16) (17) (18) . The subunit composition of the latter population is still difficult to infer. Cholinergic neurons projecting to the spinal cord are found in the medial medullary reticular formation, lateral vestibular nucleus, dorsolateral pontine tegmentum, and the red nucleus (24) . Most choline acetyltransferase (ChAT) immunoreactivity throughout the spinal cord corresponds to axons and nerve terminals (25) , but occasional cholinergic interneurons are found in lamina III and more frequently in deeper laminae (25, 26) . Electron microscopy studies showed synaptic triadic arrangements, in which a single ChAT-immunolabeled profile is presynaptic to both a central varicosity of a sensory afferent, and a dendrite postsynaptic to the central bouton (27) .
Although it is known that spinal cord is rich in GABA͞glycine-containing interneurons and 5-HT nerve terminals (28) , the relationships between these cell structures and cholinergic structures are unknown. The simplest explanation for the functional data presented above requires two cholinergic inputs, one on a GABAergic structure, which in turn influences a 5-HT terminal, and another directly on a 5-HT terminal. An anatomically plausible model for this circuit comprises a cholinergic innervation of a GABAergic interneuron innervating a 5-HT terminal and a direct cholinergic innervation of a 5-HT terminal (see Fig.  7 ). A functionally equivalent circuit can be implemented by a local circuit, comprising cholinergic, GABAergic, and serotoninergic terminals. The existence of such a microcircuit would be supported by the evidence that tetrodotoxin (i.e., blockade of axonal impulse flow) does not modify the outcome of the release experiments. In these microcircuits, ACh may not act as a classical synaptic transmitter but rather as a volume transmission signal, as already postulated in many central regions (29, 30) . More refined anatomical investigations could help us distinguish between these two hypothesis.
Functional Aspects of Nicotinic Modulation of Serotoninergic Transmission. Serotonin descending pathways to the spinal cord are classically thought to represent a main modulator of pain transmission, with complex state-dependent effects (31) (32) (33) . A major relevance of cholinergic nicotinic involvement in the spinal cord for analgesia also has recently received strong experimental support (12) . Regulation of pain sensation is therefore a possible functional outcome of the spinal nicotinic͞ serotoninergic circuit characterized in this paper. The experimental evidence on this circuit is still too limited to make strong inferences about its functional effects. However, besides nicotine agonist-elicited analgesia, an apparently paradoxical evidence for analgesia is induced by blockage of cholinergic system (see references in ref. 30) . The existence of a population of nAChRs that exerts a tonic negative modulation on [ 3 H]5-HT release through the activation of GABAergic and͞or glycinergic interneurons thus represents a possible neuronal substrate for the latter pharmacological effect.
In conclusion, we have demonstrated the existence of multiple nAChR populations exerting tonic or phasic control on 5-HT transmission in the spinal cord. These receptors may be a major target for nicotine effects on antinociception. In addition, the presence of a tonic nicotinic modulation of 5-HT release indicates that cholinergic nicotinic transmission plays a role in the physiological regulation of descending serotoninergic pathways to the spinal cord.
